Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Future Oncol. 2024;20(36):2833-2838. doi: 10.1080/14796694.2024.2400042. Epub 2024 Oct 8.
Large type 3 and type 4 gastric cancers (GC) have a significantly poor prognosis, primarily due to their high predisposition for peritoneal dissemination. The application of intraperitoneal chemotherapy has emerged as a viable therapeutic strategy for managing GC patients with peritoneal metastasis. This study is planned to enroll 37 resectable large type 3 or type 4 GC patients. These patients are scheduled to undergo a treatment comprising preoperative chemotherapy with paclitaxel, oxaliplatin and S-1, followed by D2 gastrectomy, and concluding with postoperative treatments that include prophylactic intraperitoneal chemotherapy. The study's primary objective is to evaluate the 3-year peritoneal recurrence rate. Secondary objectives are to assess the 3-year disease-free survival, 3-year overall survival and to monitor the adverse events. ChiCTR2400083253 (https://www.chictr.org.cn).
大型 3 型和 4 型胃癌（GC）预后极差，主要是因为它们易发生腹膜扩散。腹腔内化疗的应用已成为治疗 GC 腹膜转移患者的一种可行的治疗策略。本研究计划招募 37 名可切除的大型 3 型或 4 型 GC 患者。这些患者将接受包含紫杉醇、奥沙利铂和 S-1 的术前化疗，随后进行 D2 胃切除术，并在术后进行包括预防性腹腔内化疗在内的治疗。该研究的主要目标是评估 3 年腹膜复发率。次要目标是评估 3 年无病生存率、3 年总生存率，并监测不良事件。ChiCTR2400083253（[https://www.chictr.org.cn](https://www.chictr.org.cn/））。
